Results 211 to 220 of about 185,994 (381)

Prevalence and Impact of Period and Pelvic Pain in Australian Adolescents: The PPEP Talk Schools Program

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background In 2018 the Australian Government launched the world's first National Action Plan for Endometriosis (NAPE). Of its three priorities ‘Priority 1’ was ‘Education and Awareness’. In response, the Pelvic Pain Foundation of Australia was funded to deliver their Periods, Pain and Endometriosis Program (PPEP) Talk to a proportion of ...
Kate I. Tomsett   +6 more
wiley   +1 more source

Exploring Australian Women’s Attitudes Towards Paid Menstrual Leave: A Mixed‐Methods Study

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Australian lawyers, researchers and unions are advocating for the implementation of national paid menstrual leave legislation. The scarce research in this emerging field has not thoroughly explored women's attitudes towards such leave. Aim To explore Australian women's attitudes towards paid menstrual leave.
Amy Wong   +2 more
wiley   +1 more source

‘I Wish I Fought for Myself More Instead of Just Letting Doctors Dismiss Me’: A Combined Qualitative Analysis of Four Cohorts of Aotearoa New Zealand Endometriosis Patients

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Endometriosis is a chronic condition that affects around 10% of New Zealand women and people presumed female at birth, however, limitations in diagnosis and management mean patients wait a decade on average from symptom onset to diagnosis.
Katherine Ellis, Rachael Wood
wiley   +1 more source

Omalizumab reduces anaphylactic reactions and allows food introduction in food‐allergic in children with severe asthma: An observational study

open access: yesAllergy, Volume 80, Issue 4, Page 1074-1085, April 2025.
In Europe, Omalizumab is indicated for the treatment of moderate to severe asthma, but not for IgE‐mediated food allergy. We assessed the impact of Omalizumab on efficacy, safety, and the quality of life (FA‐QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat.
Stefania Arasi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy